Craig Thompson Cerevance CEO
Third time’s the charm: Cerevance’s Series B expands again
CNS-focused Cerevance expanded its Series B for the second time since 2020, reeling in another $51 million to bankroll two Phase II clinical trials and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.